Success in pharma, biotech or medtech requires a business strategy that can break through the many market hurdles.
Biobusiness is characterized by many challenging or facilitating factors. With our market research services, we aid in identifying these factors and connecting the dots.
The introduction of healthcare innovations is complicated by numerous stakeholders, fierce regulations, long time-to-market, and enormous upfront investments. Pharma, biotech, and medtech industries have an extremely high attrition rate, and standard business strategies are typically not enough. Smarter strategies are needed that comprehensively target all the challenges, bring together R&D and funding milestones and leverage key market trends and developments.
The EC is interested in boosting European competitiveness and generating jobs while transforming research results into real economic or societal value. For that, an array of non-dilutive funding schemes is available for SMEs and large companies, aimed at funding a proportion of both R&D and commercial activities.
In addition to non-dilutive funding, firms should be aware of dilutive funding options. Obtaining dilutive financing requires understanding the importance of ‘fit’ between the investor and investee, leading negotiations, and knowing how due diligence and valuations are carried out.
Mergers, acquisition, valuation and due dilligence
A fair valuation of a company becomes important when changes in shareholder structure are on the table. Especially for healthcare and life sciences innovations, valuation can be challenging as new drugs or products require years of expensive development, with pivotal clinical stages, before they reach the market and become profitable. A predetermined value range will ensure aligned expectations between stakeholders and simplify negotiations. Moreover, setting a fair value, rather than the highest value possible, ensures that in the long run the company will retain a strong fundraising position.
Our ‘Business Leadership’ brochure contains relevant insights on how to strategise over the entire life cycle of your innovation. Download the brochure and find out how to implement smarter business strategies that breaks through the many market hurdles.
Our expectations on when we will be eating cultured meat
Our expectations on when we will be eating cultured meatWhen will we be eating cultured meat? In this blog we tell you our expectations.Cultured meat companies have been optimistic in social media about when they will be able to enter the market. Years have passed by,...
Will we be eating cultured meat soon?
Will we be eating cultured meat soon? The data is telling us different storiesIn this blog we dive deeper into the projections of several market reports. How do these projections relate to the market entry of cultured meat?Introduction Although several companies have...
These are the companies that will drive cultured meat to our plate
These are the companies that will drive cultured meat to our plateThe biggest challenge for the cultured meat companies is the scale-up of the production and reduction of production costs. ttopstart helps these companies in developing smart strategies to achieve their...
Examples of biotech IPOs that quickly went public
Examples of biotech IPOs that quickly went public2020 was a record year for biotech Initial Public Offering (IPOs), with over 100 IPOs raising an aggregate $12B– nearly doubling the number of IPOs and the aggregate proceeds recorded in 2019. In this article we show...